IMMUNITYBIO, INC.
SAN DIEGO, CA

IMMUNITYBIO, INC., originally NantKwest, is an innovative clinical-stage company dedicated to developing advanced immunotherapies based in San Diego, Florida. Established on August 25, 2016, it's listed on Nasdaq under the symbol NK. The company focuses on leveraging natural killer (NK) cells-the immune system's rapid responders-to combat cancer, infectious diseases, and inflammatory conditions. These NK cells are essential because they quickly spot and eliminate stressed cells, such as those infected or transformed into cancer. IMMUNITYBIO operates in fast-growing markets with urgent healthcare needs, thanks to its robust genomics and transcriptomics discovery platform. It has a strong pipeline of clinical-stage immuno-oncology programs, including a phase 2 trial for a rare type of melanoma and upcoming trials targeting NK cells against breast cancer. Led by CEO Richard Adcock, CFO David Sachs, and Gene Jason Liljestrom, the company's mission is to revolutionize medicine by creating 'living drugs' stored in bags. These innovative NK cell-based therapies are poised to establish new standards for immune treatments across healthcare settings. In its most recent annual report from April 29, 2024, IMMUNITYBIO continued to showcase its commitment to being a leader in the field of immunotherapy.